The Altera Centauri collection has been brought up to date by Darsnan. It comprises every decent scenario he's been able to find anywhere on the web, going back over 20 years.
25 themes/skins/styles are now available to members. Check the select drop-down at the bottom-left of each page.
Call To Power 2 Cradle 3+ mod in progress: https://apolyton.net/forum/other-games/call-to-power-2/ctp2-creation/9437883-making-cradle-3-fully-compatible-with-the-apolyton-edition
Well, there are two implications. The first is that you're not invested enough in my well-being to get worked up by anything I say. But conversely, if I do happen to tick you off somehow, you're not invested enough in my well-being to stick around.
Bleh. I don't really want to play this game. Thanks for being kind. I'm sorry I'm being such a **** by not actually doing anything that anyone here (or elsewhere) suggests.
Brainsway sees growth in depression treatment, looks to new areas
Reuters
By Ari Rabinovitch 13 hours ago
JERUSALEM (Reuters) - Israeli medical device maker Brainsway expects strong growth following the launch of its treatment of depression and hopes to access new markets once its system finishes trials in treating a number of other diseases.
Brainsway developed a helmet that shoots magnetic pulses into the brain of patients with neurological disorders. The pulses stimulate neurons and improve function in the affected areas, the company says.
This method, known as transcranial magnetic stimulation, is like a tamer, safer and more precise version of electro-shock therapy and has been used for years.
Brainsway says its technology is unique because it can penetrate deeper than any other non-invasive method being used, allowing it to target areas of the brain that were until now unreachable.
The company has installed over 70 of its units, mostly in the United States, and on Tuesday reported that 2013 revenue grew to 4.29 million shekels ($1.23 million) from 1.36 million in 2012. Net loss from regular operations in 2013 narrowed to 15.41 million shekels from 21.22 million.
The company raised $11.8 million this month to boost production lines.
"We hope this trend will continue and even get stronger," Chief Executive Uzi Sofer told Reuters in an interview. "The company is aiming for thousands of installations for different diseases in the future."
Brainsway received Federal Drug Administration approval last year for treating patients with major depression disorder. Other trials are underway for fighting diseases like Parkinson's and Alzheimer's, addictions, and stress and eating disorders.
Sofer said he is already optimistic about a study being done at Harvard University on whether Brainsway's system can help with epilepsy.
Ronen Segal, chief technical officer, said "many of the big players in this market, including medical device companies and even pharmaceutical companies" have taken notice and that there is potential for collaboration in areas like distribution and research and development.
Perhaps a little ECT will snap Lori out of his funk.
“It is no use trying to 'see through' first principles. If you see through everything, then everything is transparent. But a wholly transparent world is an invisible world. To 'see through' all things is the same as not to see.”
“It is no use trying to 'see through' first principles. If you see through everything, then everything is transparent. But a wholly transparent world is an invisible world. To 'see through' all things is the same as not to see.”
Memory issues, at the least, and possibly long-term changes in brain structure.
The long term changes in structure is kinda why it works.
“It is no use trying to 'see through' first principles. If you see through everything, then everything is transparent. But a wholly transparent world is an invisible world. To 'see through' all things is the same as not to see.”
ECT has been shown to be effective for severe cases of treatment-resistant depression.
Well, then again so are most SSRIs I guess, since they're barely more effective than placebos.
This isn't strictly speaking true. SSRIs have a very mild benefit for mild depression, and their value seems to increase with the severity of the depression. There's probably no good reason to prescribe anti-depressants for people who are just going through a period of low mood, but anti-depressants do appear to have value for some.
Tweet
Comment